Published in J Neurol Neurosurg Psychiatry on March 30, 2006
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol (2011) 2.44
Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood (2011) 2.06
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis (2014) 1.58
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm (2015) 0.94
Successful treatment with rituximab of one patient with CANOMAD neuropathy. J Neurol (2009) 0.87
Outcome measures for Charcot-Marie-Tooth disease: clinical and neurofunctional assessment in children. J Peripher Nerv Syst (2011) 0.87
Clinical outcomes of patients with lumbar disc herniation, selected for one-level open-discectomy and microdiscectomy. Eur Spine J (2010) 0.86
Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition? J Neurol (2009) 0.85
The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study. PLoS One (2014) 0.84
Reliability of instrumented movement analysis as outcome measure in Charcot-Marie-Tooth disease: results from a multitask locomotor protocol. Gait Posture (2011) 0.82
Cerebellar learning distinguishes inflammatory neuropathy with and without tremor. Neurology (2013) 0.82
Changes of gait pattern in children with Charcot-Marie-Tooth disease type 1A: a 18 months follow-up study. J Neuroeng Rehabil (2013) 0.80
Polyneuropathy dysfunction scores. J Neurol Neurosurg Psychiatry (2006) 0.80
A randomized trial of diagnostic ultrasound to improve outcomes in focal neuropathies. Muscle Nerve (2015) 0.79
Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction. Ther Adv Neurol Disord (2015) 0.78
Impairment of small somatic and autonomic nerve fibres in intensive care unit patients with severe sepsis and critical illness polyneuropathy--a single center controlled observational study. BMC Neurol (2013) 0.78
Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome. Leukemia (2016) 0.78
Postural stabilization and balance assessment in Charcot-Marie-Tooth 1A subjects. Gait Posture (2014) 0.77
Value of nerve biopsy in patients with latent malignant hemopathy and peripheral neuropathy: a case series. Medicine (Baltimore) (2015) 0.77
A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Orphanet J Rare Dis (2015) 0.77
Progress in peripheral nerve disease research in the last two years. J Neurol (2013) 0.76
Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients. J Neurol (2014) 0.76
Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathy. BMC Neurol (2015) 0.75
Metabolic Syndrome, Neurotoxic 1-Deoxysphingolipids and Nervous Tissue Inflammation in Chronic Idiopathic Axonal Polyneuropathy (CIAP). PLoS One (2017) 0.75
Pure sensory chronic inflammatory polyneuropathy: rapid deterioration after steroid treatment. BMC Neurol (2015) 0.75
The Temporal Profiles of Changes in Nerve Excitability Indices in Familial Amyloid Polyneuropathy. PLoS One (2015) 0.75
Autologous cytokine-induced killer (CIK) cell immunotherapy combined with cyclophosphamide in five patients with POEMS syndrome. Clin Exp Immunol (2016) 0.75
Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies. J Neurol (2011) 0.75
Interobserver agreement for the assessment of handicap in stroke patients. Stroke (1988) 20.14
Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology (2003) 3.75
Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve (1991) 3.29
The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler (1999) 2.02
Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry (2002) 1.71
A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain (2004) 1.62
Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology (2002) 1.26
Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve (2002) 1.14
Comparison between impairment and disability scales in immune-mediated polyneuropathies. Muscle Nerve (2003) 1.04
Incidence of common compressive neuropathies in primary care. J Neurol Neurosurg Psychiatry (2006) 1.90
Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study. Eur J Neurol (2012) 1.45
Mills' and other isolated upper motor neurone syndromes: in vivo study with 11C-(R)-PK11195 PET. J Neurol Neurosurg Psychiatry (2005) 1.29
Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet (2004) 1.23
Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci (2008) 1.23
Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry (2002) 1.13
Clinimetric properties of a walking scale in peripheral neuropathy. J Neurol Neurosurg Psychiatry (2006) 1.04
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol (2006) 1.04
Guillain-Barré syndrome seen in users of isotretinoin. BMJ (2004) 0.97
134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11-13 February 2005, Naarden, The Netherlands. Neuromuscul Disord (2005) 0.97
Variable phenotypes are associated with PMP22 missense mutations. Neuromuscul Disord (2010) 0.93
Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev (2004) 0.92
Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology (2009) 0.88
Characterisation of matrix metalloproteinases and the effects of a broad-spectrum inhibitor (BB-1101) in peripheral nerve regeneration. Neuroscience (2004) 0.87
Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol (2013) 0.86
Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry (2008) 0.85
Characterization of matrix metalloproteinases in denervated muscle. Neuropathol Appl Neurobiol (2005) 0.83
Immunosuppressive treatment for non-systemic vasculitic neuropathy. Cochrane Database Syst Rev (2007) 0.81
The risk of cancer from azathioprine as a treatment for multiple sclerosis. Eur J Neurol (2004) 0.81
The measurement of disease. J Neurol Neurosurg Psychiatry (2010) 0.81
Haemophilus influenzae as a possible cause of Guillain-Barré syndrome. J Neuroimmunol (2004) 0.80
Drug therapy for chronic idiopathic axonal polyneuropathy. Cochrane Database Syst Rev (2004) 0.80
Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol (2009) 0.80
Accumulation of immunoglobulin across the 'blood-nerve barrier' in spinal roots in adoptive transfer experimental autoimmune neuritis. Neuropathol Appl Neurobiol (2002) 0.80
Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry (2010) 0.79
Immunoadsorption inferior to plasma exchange in a patient with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry (2002) 0.79
A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology (2003) 0.79
Efficacy of leukemia inhibitory factor in experimental autoimmune neuritis. J Neuroimmunol (2002) 0.78
Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry (2006) 0.78
A prospective study of physiotherapist prescribed community based exercise in inflammatory peripheral neuropathy. J Neurol (2007) 0.77
Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol (2003) 0.77
Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatry (2002) 0.77
Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. Eur J Neurol (2013) 0.77
Apolipoprotein E genotypes and clinical outcome in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry (2003) 0.76
Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry (2006) 0.76
Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev (2005) 0.76
Immunological study of hereditary motor and sensory neuropathy type 1a (HMSN1a). J Neurol Neurosurg Psychiatry (2002) 0.75